header logo image


Page 13«..10..12131415..20..»

Archive for the ‘Neuropathy’ Category

Global Neuropathy Pain Treatment Market 2020 Overview with (Covid-19) Impact Analysis of Growth, Competitive landscape and Forecast 2025 – Bandera…

Monday, June 29th, 2020

The recent research report titledGlobalNeuropathy Pain TreatmentMarket Report 2020, Forecast to 2025sheds light on critical aspects of the market by compiling the historical, current, and future outlook of the market and the factors responsible for such growth. The report contains numerical data and certified data, which is gathered from certified sources and market experts. The document offers useful guidelines for players to understand and define their strategies more efficiently in order to assist them to stay ahead of their competitors. The report includes and evaluates all the changes and shifts that are observed in the globalNeuropathy Pain Treatmentmarket. It encompasses data that is derived from historical trends and present market scenarios.

Get Free Sample Report:https://www.magnifierresearch.com/report-detail/39757/request-sample

The report then delivers information on key segmentation of the globalNeuropathy Pain Treatmentmarket including type/product, application, and geography (country/region). All segments are investigated in relation to different factors such as market size, market share, value, growth rate, other quantitative information, and forecast for 2020 to 2025 time period. The report explains market dynamics in the most detailed and easiest possible manner. Mainly, the current and future trends of the market along with opportunities for the new players who are in the process of entering the global market are highlighted in the report. It enlightens crucial details sales, product descriptions, individual market standing, pictorial representation of statistical data, and contact information of the leading companies.

Market By Companies:

The analysts have profiled leading players of the globalNeuropathy Pain Treatmentmarket, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects. The report attempts its aim to present the key manufacturers, presenting the sales, revenue, market share, and recent development for key players. The manufacturing cost structure encompasses details about the raw material, manufacturing process analysis, as well as labor costs. Overall, this section lists companies operating in every region, the prevalent competitive landscape and intensity map of key players presence in each region.

In the global market, the following companies are covered:Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group

Geographically, this report is segmented into different chief territories, containing profits, sales, growth rate and market share (percent) ofNeuropathy Pain Treatmentin the areas listed below:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Access Full Report:https://www.magnifierresearch.com/report/global-neuropathy-pain-treatment-market-report-2020-forecast-39757.html

Pivotal Highlights of Market:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@magnifierresearch.comWeb:www.magnifierresearch.com

Here is the original post:
Global Neuropathy Pain Treatment Market 2020 Overview with (Covid-19) Impact Analysis of Growth, Competitive landscape and Forecast 2025 - Bandera...

Read More...

SLE May Have Early Effect on Peripheral Nerve Function Before Electrophysiologic or Clinical Neuropathy Development – Rheumatology Advisor

Monday, June 29th, 2020

Systemic lupus erythematosus (SLE) may have an early effect on peripheral nerve function before the development of electrophysiologic or clinical neuropathy, according to study results published in Rheumatology International.

Researchers evaluated data from nerve conduction studies (NCS) in patients with SLE without clinical or electrophysiologic neuropathy and healthy control participants matched by age and sex. Data included sensory nerve action potential (SNAP), sensory nerve conduction velocities, (SNCV), and demographics. Investigators aimed to determine whether SLE could have an even earlier effect on peripheral nerve function before the development of electrophysiologic abnormalities.

A total of 61 patients with SLE without electrophysiologic neuropathy (88.5% women; median disease duration, 8 years) were included in the study. Patients had a median SLE Disease Activity Index (SLEDAI) score of 3 (range, 0-16). A total of 49.2% of patients had mild disease activity (score, 1-5), and 32.8% showed no active disease (score, 0).

Although NCS results were within the normal range, the researchers found statistically significant differences in several motor and sensory parameters between the patient and control group. Compared with control participants, among patients with SLE, distal compound muscle action potential was significantly lower in the ulnar, fibular, and posterior tibial nerves and motor nerve conduction velocities were significantly slower in the median, ulnar, and fibular nerves. In the sensory NCS, patients with SLE vs control participants showed significantly lower SNAP amplitudes in the sural nerves and slower SNCV in the median, ulnar, and sural nerves. Patients with SLE also had longer minimum F-wave latencies and their H reflexes more frequently absent.

No significant correlations were found between NCS parameters and SLEDAI or disease duration among patients with SLE; however, there were correlations between disease relapses and motor conduction velocities, specifically of the tibial and fibular nerves (r=-0.315; P =.013 and r=-0.426; P =.001).

Researchers noted that NCS measure the function of only large nerve fibers, which may represent a limitation of the study, because small peripheral nerve fibers have also been recognized to be involved in SLE.

Overall, despite having NCS results within a normal range, the data show that patients with SLE without other known causes of neuropathy experienced worse peripheral nerve function. This could suggest that SLE has early negative effects on peripheral nerve function, which supports the possibility that SLE polyneuropathy may gradually progress to development of clinical peripheral neuropathy.

Reference

Fong S-Y, Raja J, Wong K-T, Goh K-J. Systemic lupus erythematosus may have an early effect on peripheral nerve function in patients without clinical or electrophysiological neuropathy: comparison with age- and gender-matched controls [published online June 2, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04610-8

Read more:
SLE May Have Early Effect on Peripheral Nerve Function Before Electrophysiologic or Clinical Neuropathy Development - Rheumatology Advisor

Read More...

FTC Takes Dim View of Light Therapy Device – Pain News Network

Monday, June 29th, 2020

By Pat Anson, PNN Editor

Low level light therapy (LLLT) also known as laser therapy has been touted for years as a treatment for arthritis, neck and back pain, fibromyalgia, neuropathy and even spinal cord injuries.

But in the first case of its kind, the Federal Trade Commission is going to court to get the makers of a light therapy device called the Willow Curve to stop making deceptive claims that it can treat chronic pain.

When LLLT sellers say their devices will relieve pain, theyd better have the scientific proof to back it up, Andrew Smith, Director of the FTCs Bureau of Consumer Protection, said in a statement. People looking for drug-free pain relief deserve truthful information about these products.

In a complaint filed in federal court against the inventors and marketers of the Willow Curve, the FTC alleges that Dr. Ronald Shapiro and David Sutton personally made deceptive claims about the health benefits of the device and falsely claimed it was approved by the Food and Drug Administration to treat chronic pain, severe pain and inflammation.

Willow Curve is a curved plastic device that delivers low-level light and mild heat to painful areas. Its been sold online and through retailers and healthcare professionals since 2014, most recently at a price of $799.

In a 2016 commercial, television personality Chuck Woolery said the Willow Curve offers drug free pain relief for the digital age and personally promised that the Curve could change your life.

View post:
FTC Takes Dim View of Light Therapy Device - Pain News Network

Read More...

Therapeutic Options for Peripheral Neuropathy in Parkinson Disease – Neurology Advisor

Thursday, June 18th, 2020

Peripheral neuropathy is frequently seen in patients with Parkinsons disease (PD) and may increase the functional disability in these individuals. A review article published in Neurological Sciences discussed the etiology of peripheral neuropathy in the context of PD.

Previous studies have shown that peripheral neuropathy can adversely affect the lives of patients with PD. As limited data are available on small fiber neuropathy (SFN) and effective treatments for peripheral neuropathy in PD, the current review focused on the etiology, pathological mechanisms, subtypes, and management of the neurological problem in PD.

The exact pathogenic mechanism of neuropathy in PD is not entirely clear and there are many potential factors involved in the disease process, including medication, mitochondrial dysfunction, oxidative stress, and genetic susceptibility.

Diagnosis

The diagnosis is based on clinical findings along with nerve conduction studies and electromyography. As some neuropathies may present with normal findings on peripheral nerves testing, a thorough patient history is vital.

The initial investigation of peripheral neuropathy often includes glucose tolerance testing, fasting glucose levels, measurement of vitamin B12, methylmalonic acid (MMA), homocysteine (Hcy), and serum protein electrophoresis.

The diagnosis of SFN is commonly difficult to be made on the basis of peripheral nerve testing and clinical criteria are more important. Intraepidermal nerve fiber density in skin biopsy or analysis of quantitative sensory testing can help in establishing the diagnosis.

Additional tools that may aid in the diagnosis and severity assessment of SFN include autonomic testing utilizing a variety of reflex tests, intraepidermal electrical stimulation tests, corneal confocal microscopy, and microneurography.

Parkinson Disease Treatment and Neuropathy

Levodopa, the gold standard treatment for PD, may play an important role in the development of peripheral neuropathy . Long-term use of levodopa can lead to increased levels of Hcy and MMA which have been linked to neuropathy, as well as increased risk for cardiovascular diseases, neurodegenerative diseases, and neural tube defects. While many studies have pointed at B12 deficiency as the potential cause for levodopa-associated neuropathy, others suggested that folate deficiency is a more important cause.

As not all patients taking levodopa develop neuropathy, experts have suggested there may be a genetic susceptibility for the development of neuropathy in some patients. Potential candidate genes involved in PN with PD may be the parkin or MTHFR genes.

Levodopa-carbidopa intestinal gel (LCIG) are additional treatment options that were found to be associated with peripheral neuropathy. Studies have suggested a higher incidence of neuropathy in PD patients treated with duodopa or LCIG. While limited data exist on the risk for SFN, there are reports suggesting an association between LCIG treatment with neuropathy of small fibers.

Administration of catechol-O-methyltransferase (COMT) inhibitors may attenuate the levodopa-induced increase in plasma Hcy and MMA levels. However, due to the limited available data, more studies are required to better understand the efficacy of COMT inhibitors in preventing peripheral neuropathy.

Treatments of Peripheral Neuropathy

The data on treatment of peripheral neuropathy in PD remain limited and additional studies are needed to explore the benefits of cobalamin injections with folate supplements and COMT inhibitors, especially in levodopa-treated patients. Novel treatment options include electromagnetic and laser therapy.

At this point in time, COMT inhibitors, such as entacapone, are the main treatment options for peripheral neuropathy. One study has shown that the addition of COMT inhibitors may improve levodopa-associated neuropathy. However, as COMT inhibitors were not found to be effective against peripheral neuropathy secondary to causes other than levodopa exposure, other therapeutic options are needed.

Combination of vitamin B12 and methylcobalamin is recommended by some experts in the field and there are reports this may improve pain and paresthesia, but most of the data are based on studies in patients with diabetic neuropathy.

Several enzymes and genetic markers were suggested as therapeutic targets for peripheral neuropathy and have shown promising results. Furthermore, monoclonal antibodies may prove to be useful, as there are reports from patients with malignant tumors in which the combination of bendamustine-rituximab was found to alleviate immune-mediated neuropathies. Early reports have suggested a potential role for ultrasound guided vitamin B12 injections.

Future studies should investigate the toxic effects of elevated Hcy and MMA levels in patients with PD along with viable treatment options that include vitamin B12 and folate therapy. Large scale studies are required in order to understand the role and efficacy of COMT-Is along with other IPD interventions in [peripheral neuropathy], concluded the investigators.

Reference

Paul DA, Qureshi ARM, Rana AQ. Peripheral neuropathy in Parkinsons disease [published online May 1, 2020]. Neurol Sci. doi:10.1007/s10072-020-04407-4

Continue reading here:
Therapeutic Options for Peripheral Neuropathy in Parkinson Disease - Neurology Advisor

Read More...

COVID 19 Impact on Neuropathy Pain Treatment Market 2020 Industry Size, Share, Applications, Manufacturers and Forecasts to 2026 – Farmers Ledger

Thursday, June 18th, 2020

Neuropathy Pain Treatment Market 2020 Industry increasing incidence of neuropathic pain caused by damage or disease affecting the somatosensory nervous system. Growing awareness among patients and increase in the demand for generic drugs boost the market growth. However, severe side effects of opioids and steroids and rising costs of branded drugs might hamper the market growth.

For Sample Copy of this Report @https://www.orianresearch.com/request-sample/956157

Neuropathy Pain Treatment Marketreport offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Industry Segment by Manufacturers:

Report Covers Market Segment by Types:

Global Neuropathy Pain Treatment Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report @https://www.orianresearch.com/checkout/956157

Report Covers Market Segment by Applications:

Key Benefits of the Report:

Target Audience:

Inquire more about Neuropathy Pain Treatment Market report @https://www.orianresearch.com/enquiry-before-buying/956157

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the

Key Industry Participants (KIPs) which typically include:

Table of Content

1 Executive Summary

2 Methodology And Market Scope

3 Neuropathy Pain Treatment Market Industry Outlook

4 Neuropathy Pain Treatment Market By End User

5 Neuropathy Pain Treatment Market Type

6 Neuropathy Pain Treatment Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

See the original post here:
COVID 19 Impact on Neuropathy Pain Treatment Market 2020 Industry Size, Share, Applications, Manufacturers and Forecasts to 2026 - Farmers Ledger

Read More...

Chemotherapy Induced Peripheral Neuropathy Treatment Market to witness an impre – News by aeresearch

Thursday, June 18th, 2020

The research report on Chemotherapy Induced Peripheral Neuropathy Treatment market Size provides a thorough assessment of this business vertical. As per the study, the market is predicted to accumulate significant revenues and showcase a substantial growth rate during the estimated timeframe.

The Chemotherapy Induced Peripheral Neuropathy Treatment market report is a thorough investigation of the industry in terms of consumption and production. The report, based on the production facet, encompasses details regarding the manufacturing structure and profit margins of the renowned manufacturers. The price incurred by the companies to produce, store, and sell one unit of a product across the various geographies over the analysis period are also included in the study.

Speaking of the consumption aspect, the study details the consumption value and consumption volume of the products in question. Data pertaining to the individual sales price along with the import and export patterns spanning various territories are delivered in the report. Additionally, the report also predicts the production and consumption patterns over the assessment period.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/219125

Key pointers from the competitive landscape:

An outline of the regional landscape:

A brief overview of the product spectrum:

A summary of the application terrain:

In conclusion, the report evaluates the Chemotherapy Induced Peripheral Neuropathy Treatment market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are duly presented in the report.

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/219125

Originally posted here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market to witness an impre - News by aeresearch

Read More...

Are Trump’s Problems with Walking, Drinking Water Due to Hydroxychloroquine? – American Council on Science and Health

Thursday, June 18th, 2020

As a vascular surgeon, I am well acquainted with what we call gait disturbances, an abnormal walk. I am sure many of you have seen individuals who have suffered from a stroke with partial loss of their leg, which results in a walk that is less fluid.

There are many diagnostic possibilities responsible for a change in our gait. I am, unfortunately, most familiar with structural alterations, e.g., loss of a portion of the foot, or unequal length of limbs. There can be issues related to injury;think of how we might limp after injuring our knee. And there can be neurologic causes, related to nerve injury, that leave the muscles weaker or altering proprioception the sense of the position of the body in space, which is sensory feedback necessary for balance.

In watching the video of President Trump walking down the ramp, he does seem to be favoring one leg. To be fair, his explanation that is was a slippery incline may indeed be true.

But let's now consider the video of him pausing his speech to drink a bit of water. In the video, the president raises a glass, but he can't quite lift it to his mouth. He tilts his head down to get closer to the glass before using his left hand to fully raise the glass to his lips. From a diagnostic point of view, that changes the differential. Becausewhile the gait disturbance has multiple causes, the lifting of the glass suggests a problem of muscular strength.*

So now, we have issues with two sets of muscles:the legsand arms. It would be odd to have an injury that involved two areas not be reported, especially involvingthe president. The same holds for structural problems, and that moves neuropathy up the differential list. What could be the source of a new-onset neuropathy? I know little of the presidents medical status. That is, except for one, perhaps salient fact:he said he has been taking hydroxychloroquine.

Physicians have rightly been concerned about the cardiac effects of this medication on the hearts rhythm. But hydroxychloroquine has some other, less frequently cited adverse effects. If you read the FDA requiredpackage insertunder adverse effects, here is what you will find:

Musculoskeletal and connective tissue disorders: Sensorimotor disorder, skeletal muscle myopathy orneuromyopathy leading to progressive weakness and atrophy of proximal muscle groups, depression of tendon reflexes and abnormal nerve conduction. [Emphasis added]

Proximal muscles are those closest to our body, like the muscles of the upper arm that raise the arm and hand. Or the muscles of the thigh that are actively involved in all phases of walking. It is not an overly common adverse side effect.It is probably relatively rare, but a quick search uncovered areviewof 10 cases of hydroxychloroquine associatedneuromyopathy.

Again, let me emphasize that I am not attempting to diagnose an illness without performing both a careful history or physical examination. I am trying to point out a fallacy in the therapeutic use of medications. as there is always a tradeoff between benefits and risk. Always. In reporting on the presidents decision to treat himself with hydroxychloroquine on May 18, the New York Times reported, Mr. Trump continued, explaining that his decision to try the drug was based on one of his favorite refrains: What do you have to lose?

What indeed? It would be ironic that the drug President Trump described as a game-changer might instead turn out to be a gait-changer.

Note

*This, by the way, is a reasonable example of Bayesian thinking, where I adjust my original differential (probabilities) based on further information.

The rest is here:
Are Trump's Problems with Walking, Drinking Water Due to Hydroxychloroquine? - American Council on Science and Health

Read More...

Diet and exercise are first prescription to try for prediabetes – STLtoday.com

Thursday, June 18th, 2020

Your husband is at risk, and the fact that the symptoms are recent means he should look at this as a wake-up call. Changing his lifestyle dramatically now can not only lead to improvement in symptoms (or at least they wont get worse), but it will also reduce his risk of heart attack and stroke.

There are many places to get help: His doctor, a registered dietitian nutritionist and a diabetes nurse educator all are excellent potential sources of information, but he has to make the decision to start the lifestyle change.Vitamins do not help diabetic neuropathy. If he can start making the changes, I hope he will find, as most people have, that his quality of life and sense of well-being are so much better that he will not want to stop his healthier lifestyle. Medications may be helpful, but the primary treatment is diet and exercise.

Dear Dr. Roach My wife smoked for many years and finally quit with the help of nicotine gum that is 4 milligrams each. Since quitting almost 20 years ago, she continues to use about 12 pieces of nicotine gum per day. Does ingesting this much nicotine in this manner put her at risk for developing some type of cancer from the nicotine? T.D.

Answer No, nicotine is not carcinogenic, that is to say cancer-causing. In large doses, it is dangerous, but the doses she is taking are not at least, for a person used to them. Early signs of nicotine toxicity are excess salivation, nausea and vomiting.

Visit link:
Diet and exercise are first prescription to try for prediabetes - STLtoday.com

Read More...

Roach: Diet and exercise are first prescription to try for prediabetes – LubbockOnline.com

Thursday, June 18th, 2020

DEAR DR. ROACH: My husband is a 50-year-old prediabetic who has recently experienced burning feet. He refuses to think it's his high-carb diet (bread three times a day, chips, ice cream) and instead thinks he just needs some vitamins for foot pain. Could you please explain why and how what he eats affects everything he's experiencing? -- Anon.

ANSWER: Diabetic neuropathy is a condition found in people who have had diabetes for years. It causes different symptoms in different people, but pain (often burning in character) and numbness are most common. The underlying cause is uncertain, but seems to be a combination of factors leading to nerve damage.

Prediabetes, often along with the other components of metabolic syndrome -- including high blood pressure, excess abdominal fat and high cholesterol or triglycerides -- may also bring on a neuropathy with very similar symptoms. Other causes, especially vitamin B12 deficiency, are appropriate to evaluate before determining the condition is most likely due to diabetes or prediabetes.

There are no specific treatments for the neuropathy, although there are medications to ease symptoms. Treatment of the underlying metabolic syndrome is therefore of the utmost importance, and the two most important treatments are diet and exercise. Avoiding simple carbohydrates, such as found in bread and chips, or the sugars in ice cream, is paramount. Regular exercise has an independent effect that adds to the effectiveness of the dietary changes.

Your husband is at risk, and the fact that the symptoms are recent means he should look at this as a wake-up call. Changing his lifestyle dramatically now can lead not only to improvement in symptoms (or at least they won't get worse), but it will also reduce his risk of heart attack and stroke.

There are many places to get help: His doctor, a registered dietitian nutritionist and a diabetes nurse educator all are excellent potential sources of information, but he has to make the decision to start the lifestyle change. Vitamins do not help diabetic neuropathy. If he can start making the changes, I hope he will find, as most people have, that his quality of life and sense of well-being are so much better that he will not want to stop his healthier lifestyle. Medications may be helpful, but the primary treatment is diet and exercise.

DEAR DR. ROACH: My wife smoked for many years and finally quit with the help of nicotine gum that is 4 milligrams each. Since quitting almost 20 years ago, she continues to use about 12 pieces of nicotine gum per day. Does ingesting this much nicotine in this manner put her at risk for developing some type of cancer from the nicotine? -- T.D.

ANSWER: No, nicotine is not carcinogenic, that is to say cancer-causing. In large doses, it is dangerous, but the doses she is taking are not -- at least, for a person used to them. Early signs of nicotine toxicity are excess salivation, nausea and vomiting.

There are many toxic substances in tobacco, some of which are cancer-causing. The tobacco does not need to be burned; chewing tobacco and snuff increase the risk of oral cancer. About half of all people who smoke will die because of smoking-related illness. Even one cigarette a day has significant long-term health risks.

Although it's not ideal that she continues to use nicotine gum (and it's not cheap), there is no doubt that the gum is much, much safer for her than continuing to smoke.

Readers may email questions to ToYourGoodHealth@med.cornell.edu. (c) 2020 North America Syndicate Inc.

Originally posted here:
Roach: Diet and exercise are first prescription to try for prediabetes - LubbockOnline.com

Read More...

Neuropathy Pain Treatment Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 – Cole of Duty

Tuesday, June 9th, 2020

A new market report by Market Research Intellect on the Neuropathy Pain Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Neuropathy Pain Treatment sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=275286&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Neuropathy Pain Treatment manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Neuropathy Pain Treatment Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=275286&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Neuropathy Pain Treatment. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=275286&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Neuropathy Pain Treatment market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Follow this link:
Neuropathy Pain Treatment Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

Read More...

Peripheral Neuritis Treatment Market to Grow Significantly With Increasing Advancements in Technology, Says QYR – Cole of Duty

Tuesday, June 9th, 2020

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Peripheral Neuritis Treatment market. It informs readers about key trends and opportunities in the global Peripheral Neuritis Treatment market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Peripheral Neuritis Treatment market.

Key companies operating in the global Peripheral Neuritis Treatment market include , Pfizer, Depomed, Novartis, Biogen, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Bristol-Myers Squibb, Baxter Healthcare, Johnson & Johnson, Teva Pharmaceuticals Peripheral Neuritis Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1456206/global-peripheral-neuritis-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Peripheral Neuritis Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Peripheral Neuritis Treatment Market Segment By Type:

, Diabetic Peripheral Neuropathy (DPN), Chemotherapy-induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy (IPN), Others

Global Peripheral Neuritis Treatment Market Segment By Application:

, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Peripheral Neuritis Treatment market.

Key companies operating in the global Peripheral Neuritis Treatment market include , Pfizer, Depomed, Novartis, Biogen, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Bristol-Myers Squibb, Baxter Healthcare, Johnson & Johnson, Teva Pharmaceuticals Peripheral Neuritis Treatment

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1456206/global-peripheral-neuritis-treatment-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Peripheral Neuritis Treatment Revenue1.4 Market Analysis by Type 1.4.1 Global Peripheral Neuritis Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Diabetic Peripheral Neuropathy (DPN) 1.4.3 Chemotherapy-induced Peripheral Neuropathy (CIPN) 1.4.4 Idiopathic Peripheral Neuropathy (IPN) 1.4.5 Others1.5 Market by Application 1.5.1 Global Peripheral Neuritis Treatment Market Share by Application: 2020 VS 2026 1.5.2 Hospital Pharmacies 1.5.3 Retail Pharmacies 1.5.4 Online Pharmacies 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions2.1 Peripheral Neuritis Treatment Market Perspective (2015-2026)2.2 Peripheral Neuritis Treatment Growth Trends by Regions 2.2.1 Peripheral Neuritis Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Peripheral Neuritis Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Peripheral Neuritis Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Peripheral Neuritis Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Peripheral Neuritis Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Peripheral Neuritis Treatment Players by Market Size 3.1.1 Global Top Peripheral Neuritis Treatment Players by Revenue (2015-2020) 3.1.2 Global Peripheral Neuritis Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Peripheral Neuritis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Peripheral Neuritis Treatment Market Concentration Ratio 3.2.1 Global Peripheral Neuritis Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Peripheral Neuritis Treatment Revenue in 20193.3 Peripheral Neuritis Treatment Key Players Head office and Area Served3.4 Key Players Peripheral Neuritis Treatment Product Solution and Service3.5 Date of Enter into Peripheral Neuritis Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Peripheral Neuritis Treatment Historic Market Size by Type (2015-2020)4.2 Global Peripheral Neuritis Treatment Forecasted Market Size by Type (2021-2026) 5 Peripheral Neuritis Treatment Breakdown Data by Application (2015-2026)5.1 Global Peripheral Neuritis Treatment Market Size by Application (2015-2020)5.2 Global Peripheral Neuritis Treatment Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Peripheral Neuritis Treatment Market Size (2015-2020)6.2 Peripheral Neuritis Treatment Key Players in North America (2019-2020)6.3 North America Peripheral Neuritis Treatment Market Size by Type (2015-2020)6.4 North America Peripheral Neuritis Treatment Market Size by Application (2015-2020) 7 Europe7.1 Europe Peripheral Neuritis Treatment Market Size (2015-2020)7.2 Peripheral Neuritis Treatment Key Players in Europe (2019-2020)7.3 Europe Peripheral Neuritis Treatment Market Size by Type (2015-2020)7.4 Europe Peripheral Neuritis Treatment Market Size by Application (2015-2020) 8 China8.1 China Peripheral Neuritis Treatment Market Size (2015-2020)8.2 Peripheral Neuritis Treatment Key Players in China (2019-2020)8.3 China Peripheral Neuritis Treatment Market Size by Type (2015-2020)8.4 China Peripheral Neuritis Treatment Market Size by Application (2015-2020) 9 Japan9.1 Japan Peripheral Neuritis Treatment Market Size (2015-2020)9.2 Peripheral Neuritis Treatment Key Players in Japan (2019-2020)9.3 Japan Peripheral Neuritis Treatment Market Size by Type (2015-2020)9.4 Japan Peripheral Neuritis Treatment Market Size by Application (2015-2020) 10Key Players Profiles10.1 Pfizer 10.1.1 Pfizer Company Details 10.1.2 Pfizer Business Overview and Its Total Revenue 10.1.3 Pfizer Peripheral Neuritis Treatment Introduction 10.1.4 Pfizer Revenue in Peripheral Neuritis Treatment Business (2015-2020)) 10.1.5 Pfizer Recent Development10.2 Depomed 10.2.1 Depomed Company Details 10.2.2 Depomed Business Overview and Its Total Revenue 10.2.3 Depomed Peripheral Neuritis Treatment Introduction 10.2.4 Depomed Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.2.5 Depomed Recent Development10.3 Novartis 10.3.1 Novartis Company Details 10.3.2 Novartis Business Overview and Its Total Revenue 10.3.3 Novartis Peripheral Neuritis Treatment Introduction 10.3.4 Novartis Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.3.5 Novartis Recent Development10.4 Biogen 10.4.1 Biogen Company Details 10.4.2 Biogen Business Overview and Its Total Revenue 10.4.3 Biogen Peripheral Neuritis Treatment Introduction 10.4.4 Biogen Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.4.5 Biogen Recent Development10.5 GlaxoSmithKline 10.5.1 GlaxoSmithKline Company Details 10.5.2 GlaxoSmithKline Business Overview and Its Total Revenue 10.5.3 GlaxoSmithKline Peripheral Neuritis Treatment Introduction 10.5.4 GlaxoSmithKline Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.5.5 GlaxoSmithKline Recent Development10.6 Sanofi 10.6.1 Sanofi Company Details 10.6.2 Sanofi Business Overview and Its Total Revenue 10.6.3 Sanofi Peripheral Neuritis Treatment Introduction 10.6.4 Sanofi Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.6.5 Sanofi Recent Development10.7 Eli Lilly and Company 10.7.1 Eli Lilly and Company Company Details 10.7.2 Eli Lilly and Company Business Overview and Its Total Revenue 10.7.3 Eli Lilly and Company Peripheral Neuritis Treatment Introduction 10.7.4 Eli Lilly and Company Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.7.5 Eli Lilly and Company Recent Development10.8 Bristol-Myers Squibb 10.8.1 Bristol-Myers Squibb Company Details 10.8.2 Bristol-Myers Squibb Business Overview and Its Total Revenue 10.8.3 Bristol-Myers Squibb Peripheral Neuritis Treatment Introduction 10.8.4 Bristol-Myers Squibb Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.8.5 Bristol-Myers Squibb Recent Development10.9 Baxter Healthcare 10.9.1 Baxter Healthcare Company Details 10.9.2 Baxter Healthcare Business Overview and Its Total Revenue 10.9.3 Baxter Healthcare Peripheral Neuritis Treatment Introduction 10.9.4 Baxter Healthcare Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.9.5 Baxter Healthcare Recent Development10.10 Johnson & Johnson 10.10.1 Johnson & Johnson Company Details 10.10.2 Johnson & Johnson Business Overview and Its Total Revenue 10.10.3 Johnson & Johnson Peripheral Neuritis Treatment Introduction 10.10.4 Johnson & Johnson Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.10.5 Johnson & Johnson Recent Development10.11 Teva Pharmaceuticals 10.11.1 Teva Pharmaceuticals Company Details 10.11.2 Teva Pharmaceuticals Business Overview and Its Total Revenue 10.11.3 Teva Pharmaceuticals Peripheral Neuritis Treatment Introduction 10.11.4 Teva Pharmaceuticals Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.11.5 Teva Pharmaceuticals Recent Development 11Analysts Viewpoints/Conclusions 12Appendix12.1 Research Methodology 12.1.1 Methodology/Research Approach 12.1.2 Data Source12.2 Disclaimer12.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original:
Peripheral Neuritis Treatment Market to Grow Significantly With Increasing Advancements in Technology, Says QYR - Cole of Duty

Read More...

Diabetic Peripheral Neuropathy Market is Anticipated to Increase Owing to a Rich and Robust Pipeline – Press Release – Digital Journal

Wednesday, June 3rd, 2020

"Diabetic Peripheral Neuropathy Market"

According to DelveInsight, the Diabetic Peripheral Neuropathy Market in 7MM was found to be approximately USD 2,275.52 Million in 2017 and is set to increase by 2030.

Geography Covered

Study Period: 20172030

Diabetic Peripheral Neuropathy Disease Overview

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.

As per the American Diabetes Association, most common among diabetic neuropathies are chronic DPN, accounting for about 75% of the diabetic neuropathies.

Diabetic Peripheral Neuropathy Epidemiology

DelveInsights estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 20172030.

Visit to know more about the report: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market

Diabetic Peripheral Neuropathy Market: Treatment and Emerging Therapies

The rising global burden of diabetes is spurring an increase in the prevalence of diabetic neuropathy and neuropathic pain. At present, there are no FDA-approved pathogenetic therapies for DPN and the efficacy of treatments for painful DPN is limited.

The management of pain remains the key aspect of symptom treatment for DPN. The current medications fall into categories, such as antidepressants, anticonvulsants, topical agents and opioids. Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group.

Treatments currently approved by both FDA and EMA for pain associated with DPN includepregabalin, duloxetine, and extended-release tapentadol and capsaicin 8% patch. However, no treatments have been approved for the prevention or reversal of DPN.

According to DelveInsight, the Diabetic Peripheral Neuropathy Market in 7MM was found to be approximately USD 2,275.52 Million in 2017 and is set to increase by 2030.

Request for sample pages: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies.

The key pharma players working in Diabetic Peripheral Neuropathy Market are:

1. Helixmith,

2. Aptinyx

3. WinSanTor, Inc

4. Regenacy Pharmacuticals

5. Ichnos Science

6. Novaremed

7. Grnenthal GmbH

8. Glenmark Pharmaceuticals

9. AstraZeneca

10. Angelini

And many others

Diabetic Peripheral Neuropathy Report Insights

Table of Contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet needs

9. Diabetic Peripheral Neuropathy Marketed Drugs

10. Diabetic Peripheral Neuropathy Emerging drugs

11. Diabetic Peripheral Neuropathy Market Size

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Diabetic Peripheral Neuropathy Market Drivers

14. Diabetic Peripheral Neuropathy Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: http://www.delveinsight.com/

See more here:
Diabetic Peripheral Neuropathy Market is Anticipated to Increase Owing to a Rich and Robust Pipeline - Press Release - Digital Journal

Read More...

Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight – PRNewswire

Wednesday, June 3rd, 2020

LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.

DelveInsight added a new report titled "Diabetic Peripheral Neuropathy MarketInsights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from Diabetic Peripheral Neuropathy Market report are:

Request for sample pages to know more onDiabetic Peripheral Neuropathy Epidemiology and Market Forecast

Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.

There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.

The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral NeuropathyPrevalent in the US in 2020.

Click here to know more onDiabetic Peripheral Neuropathypipeline

Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.

There aremany key players robustly involved in developing potential drugs and they are a ray of hopefor DPN patients such as:1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others

The key players involved in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Grnenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others

The reasons for buying Diabetic Peripheral Neuropathy market report:

Table of contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM

6.3. United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. United Kingdom

6.10. Japan

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet need

9. Diabetic Peripheral Neuropathy Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grnenthal

9.3. Tarlige: Daiichi Sankyo

10. Diabetic Peripheral Neuropathy Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.3. NYX-2925: Aptinyx

10.4. WST-057: WinSanTor

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.6. Cebranopadol: Grnenthal

10.7. ISC 17536: Ichnos Science

10.8. NRD135S.E1: Novaremed

10.9. MEDI7352: AstraZeneca

10.10. Trazodone/Gabapentin: Angelini

11. Diabetic Peripheral Neuropathy Market Size

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM

11.4. United States

11.5. EU5

11.6. Germany

11.7. France

11.8. Italy

11.9. Spain

11.10. United Kingdom

11.11. Japan

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report:https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Related Reports:

Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:

Shruti Thakur[emailprotected]+91-9650213330DelveInsight

SOURCE DelveInsight Business Research, LLP

More here:
Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight - PRNewswire

Read More...

Updates on Auditory Neuropathy Spectrum Disorder : The Hearing Journal – LWW Journals

Wednesday, June 3rd, 2020

Auditory neuropathy was first described in 1996 by Arnold Starr, MD, and colleagues as a hearing impairment that, by behavioral and physiological testing, were compatible with a disorder of the auditory portion of the eighth cranial nerve.1 Since then, research has found notable hallmarks of normal outer hair cell function in the presence of severely abnormal or absent auditory brainstem evoked potentials. When measurable, speech discrimination scores are proportionally lower than expected for the degree of hearing loss, complementing a patient's hearing difficulty (e.g., I can hear sound but can't understand speech, especially in noise). Also, a host of neurological, audiological, and clinical features and findings reveals a variety of causes, genotypes and phenotypes, comorbidities, and auditory consequences. The desynchrony created by auditory neuropathy impairs neural processing, thereby resulting in a series of perceptual disadvantages and compromiseand to various degrees, disabling communication and auditory scene analysis. Whether occuring from a peripheral or a central site, the effects of temporal discord are universal: Auditory temporal processing determines our understanding of speech, our appreciation of music, being able to localize a sound source, and to listen to a person in a noisy crowd.2

Auditory system delineating the inner hair cells (sensory), pre- and postsynaptic portions (synapse), and the spiral ganglion and auditory nerve (neural). Cochlear implantation bypasses the sensory and synaptic portions providing a time-locked signal to the neural partition.6 Health loss, research, neuropathy.

Since the discovery of auditory neuropathy, researchers have described various sites of the lesion along the neural pathway. Auditory neuropathy is a condition of abnormal neural encoding of acoustic signals in the presence of normal sensory transduction and amplification properties of the outer hair cells.3 Potential disorders and sites of lesions include (1) presynaptic disorders affecting inner hair cells and ribbon synapses; (2) postsynaptic disorders affecting unmyelinated auditory nerve dendrites; (3) postsynaptic disorders affecting auditory ganglion cells and their myelinated axons and dendrites; and (4) central neural pathway disorders affecting the auditory brainstem.4 In some cases, auditory neuropathy may include brainstem connections such as those reported in individuals with multiple brainstem neuropathies.5 These structures are divided into three primary partitions responsible for encoding sound: sensory, synaptic, and neural (Fig. 1).6

Fortunately, advancements in auditory electrophysiology and psychophysical tests have made the identification of the site of lesion and functionality more available to clinical practice. These tools have greatly improved diagnosis, treatment selection, and outcome prediction. Having a basic understanding of this complex topic is useful for audiologists and ENT physicians because auditory neuropathy spectrum disorders (ANSDs) occur in children, adults, and seniors due to aging, noise exposure, trauma, and disease. Take note of these pearls of wisdom that will aid in evaluating, diagnosing, and discussing hearing loss and treatments with patients of all ages.

Research highlights relevant to audiology practices include notable information on ANSD prevalence, causations, symptoms, evaluation, testing, and treatments.

PREVALENCE. One in 7,000 neonates evaluated through newborn hearing screening has been found to have an abnormal auditory nerve function.4 ANSD is estimated to occur in one in 10 children with permanent hearing loss.7 Studies suggest that a considerable number of cases may occur in the well-baby population since newborn hearing screenings are typically based on otoacoustic emissions (OAEs)8 rather than auditory brainstem response (ABR)7 or simultaneous testing.

The incidence of patients with auditory neuropathy or cochlear synaptopathy9 in the general population is unknown. However, 10 percent of patients seen at Massachusetts Eye and Ear complain of hearing difficulty in the presence of clinically normal hearing,10 suggesting that ANSD and central auditory processing disorder (CAPD) evaluations should be considered for this population.

CAUSATION. Syndromic and nonsyndromic disorders cause auditory neuropathy through synaptic and neural pathways. Auditory neuropathy varies by etiology, onset age, site of lesion, auditory behavior, and the presence or absence of other peripheral neuropathies.11 Prematurity, low birth weight, hyperbilirubinemia, anoxia, otoferlin gene mutations, Waardenburg's syndrome, Charcot-Marie-Tooth disease (hereditary motor and sensory neuropathy), ototoxic drugs, infection, and cranial nerve hypoplasia, among others, have been reported as risk factors. Genetic disorders account for most cases, especially in children. A mild head injury can cause cranial nerve injury, including an injury to the eighth nerve, although this is less frequent.12

Auditory synaptopathy impairs sound encoding at the synapses between inner hair cells and spiral ganglion neurons.3 Should discrimination difficulty accompany normal hearing sensitivity by standard audiometry (some with ultra-high-frequency hearing loss) and a history of noise exposure or advanced aging, the patient may have cochlear synaptopathy or hidden hearing loss.13

SYMPTOM. Psychophysical testing reveals auditory neuropathy results in perceptual consequences that impair speech discrimination and auditory scene analysis. Unlike cochlear impairments, this condition has a minor effect on loudness, high-frequency pitch discrimination, or localization based on level differences. On the other hand, auditory neuropathy patients have deficiencies in time-based perceptions such as pitch discrimination at low frequencies, temporal integration and modulation detection, binaural beats, masking paradigms, hearing signals in noise, gap detection, and localization using interaural timing.14

Children with this condition may have excellent visual cognition but exhibit poor auditory skills.15 Speech may develop normally or be delayed. Speech discrimination may range from no difficulty in quiet with issues hearing in noise to profound hearing loss in quiet.7

Adults who acquire auditory neuropathy complain of difficulty understanding speech and deafness in background noise. They have difficulty with music perception, sound fading, and localization, and often dislike noise. They may be unemployable for certain jobs, cannot hear well on the telephone, and prefer online jobs and email for communication.

Patients with auditory neuropathy may have constant low-frequency bilateral tinnitus (< 1,000 Hz) with pitch matching at the greatest degree of hearing loss, typically 10 to 15 dB SL.16

In cases of comorbid peripheral neuropathy or a diagnosis of Charcot-Marie-Tooth disease (the most common inherited neurological disease), hearing loss occurs several years before the onset of other symptoms.3

Auditory neuropathy may be progressive as a result of several conditions. These include genetic mutations, mitochondrial disorders, autoimmune anomalies, degenerative changes from aging and noise trauma, toxic metabolic disorders, and nutritional deficits.3

Mutations of the OTOF gene (otoferlin) can express as a transient temperature-sensitive auditory neuropathy, which resolves once the increased body temperature is resolved.17,18 A gene responsible for autosomal dominant auditory neuropathy (AUNA1) was found in a family of European ancestry. The average age of symptom onset was 19 years old.19

EVALUATION. Audiological testing may cover a wide variety of evaluations depending on the patient's age. These may include testing of pure tones, hearing in noise, otoacoustic emissions with and without crossed suppression, acoustic reflexes, cochlear microphonics, summating potentials, ABR, and cortical auditory-evoked potential (CAEP), as well as tympanometry and electrocochleography (ECochG).

Medical evaluation includes an MRI of the inner ears, retrocochlear and brainstem structures, a complete history and genetic analysis, and a physical examination. Audiometric configurations can be downsloping, flat, or high frequency. Low-frequency or reverse curve loss is more prominent, potentially as a result of phase-locking difficulty caused by desynchrony compared to higher frequencies at approximately 2,000 Hz.1

In some cases of auditory neuropathy, patients may have abnormalities in the cochlear microphonic, low amplitude wave V without a wave I, and absent TEOAEs.20 Despite compromised ABRs, CAEPs can often be recorded in ANSD patients. Emerging research highlights the application of CAEP in estimating the behavioral thresholds in this population.21 A slower time constant and recovery allow for better synchrony and reliability.

Vestibular neuropathy may accompany findings of auditory and peripheral neuropathies. Some patients with abnormal caloric responses may be asymptomatic in the presence of peripheral neuropathy.22 The prevalence of at least one vestibular complaint with auditory neuropathy is 20 percent.23 Using the Dizziness Handicap Inventory, the severity of balance complaints is reported as moderate.24

The British Society of Audiology has published comprehensive recommendations for testing young infants who fail newborn screening or considered at risk for ANSD. Testing for this cohort starts with a 4kHz tpABR, followed by another test to identify sensorineural or mixed hearing loss or ANSD, such as a bone conduction ABR, 1 kHz or 0.5 kHz ABR, click ABR, OAE, and/or cochlear microphonics, tympanometry, or stapedial reflexes testing.7 In premature babies, ABR retesting over weeks and months should be conducted to identify those with delayed maturation.

TREATMENT. Goals for newborns with suspected ANSD are to provide appropriate treatment and begin rehabilitation within the first six months. Visual cueing is important in the early stages until the infant's hearing level and diagnosis can be established. Hearing aids, cochlear implants (CI), and rehabilitation options are guided by the locus of the lesion, the severity of synaptic degeneration, concomitant sensory loss, neural competency, and behavioral responses.

Hearing aids are not effective in many cases, although some studies suggest that a trial with amplification, which may include wireless communication, may be recommended based on the patient's degree of hearing loss, age, comorbidities, and behavioral factors. Amplification is typically fit to standard formulas. Enhanced spectral cues and low-pass filtering in the hearing aid prescription are suggested in some cases.7

Regarding CIs, assessment of spiral ganglion health using intraoperative ECochG measurements has become one of the best predictors of CI outcomes. Cochlear implantation results are better when the site of lesion is sensory or synaptic since the CI bypasses these regions to simulate the neural partition (Fig. 1).6 A new hypothesis suggests that binaural cues improve perception in noise. Screening for residual binaural sensitivity might be important when evaluating a patient with AN's candidacy for hearing aids and/or cochlear implants.25

Based on CAEP testing, children more likely show maturation effects within six months and age-appropriate responses when CIs are fitted under the age of two.26

Thoughts on something you read here? Write to us at HJ@wolterskluwer.com

Abdala C, Sininger YS, Starr A (2000). Distortion product otoacoustic emission suppression in subjects with auditory neuropathy, Ear Hear, Dec; 21(6), 542-553. DOI:10.1097/00003446-200012000-00002

CDC (2017). Hearing loss in children; 2017 Hearing Screening Summary. Retrieved online. https://www.cdc.gov/ncbddd/hearingloss/2017-data/01-data-summary.html

Jutras B, Russell LJ, Hurteau AM, Chapdelaine M (2003). Auditory neuropathy in siblings with Waardenburg's syndrome, Int J Ped Otorhinolaryngol, Oct; 67(10), 1133-1142. DOI: 10.1016/s0165-5876(03)00200-3

More:
Updates on Auditory Neuropathy Spectrum Disorder : The Hearing Journal - LWW Journals

Read More...

COVID-19 Impact on Peripheral Neuropathy Treatment Market to Witness a Pronounce Growth During 2020-2025, Top key players are Eli Lilly, Johnson &…

Wednesday, June 3rd, 2020

COVID-19 Impact on Peripheral Neuropathy Treatment Market, Global Research Reports 2020-2021

In 2019, the global COVID-19 Impact on Peripheral Neuropathy Treatment Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.

COVID-19 Impact on Peripheral Neuropathy Treatment Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global COVID-19 Impact on Peripheral Neuropathy Treatment Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered. The analysis of each segment in-detailed with various point views; that include the availability of data, facts, and figures, past performance, trends, and way of approaching in the market. The COVID-19 Impact on Peripheral Neuropathy Treatment Market report also covers the in-depth analysis of the market dynamics, price, and forecast parameters which also include the demand, profit margin, supply and cost for the industry.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the COVID-19 Impact on Peripheral Neuropathy Treatment Market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

In-depth analysis of expansion and growth strategies obtained by Key players and their effect on competition market growth. The research report also provides precise information on your competitors and their planning. All of the above will help you to make a clear plan for top-line growth.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-133713

Top key players @ Major competitors identified in this market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Aptinyx, Regenacy Pharmaceuticals, TEVA Pharmaceutical Industries, Immune Pharmaceuticals, etc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of COVID-19 Impact on Peripheral Neuropathy Treatment Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global COVID-19 Impact on Peripheral Neuropathy Treatment Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they COVID-19 Impact on Peripheral Neuropathy Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the key market trends impacting the growth of the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the challenges to market growth?

Who are the key vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the market opportunities and threats faced by the vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia COVID-19 Impact on Peripheral Neuropathy Treatment Market;

3.) The North American COVID-19 Impact on Peripheral Neuropathy Treatment Market;

4.) The European COVID-19 Impact on Peripheral Neuropathy Treatment Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

COVID-19 Impact on Peripheral Neuropathy Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @https://www.lexisbusinessinsights.com/request-sample-133713

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Business Development Manager)

US: +1 210 907 4145

APAC: +91 9867799788

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Go here to read the rest:
COVID-19 Impact on Peripheral Neuropathy Treatment Market to Witness a Pronounce Growth During 2020-2025, Top key players are Eli Lilly, Johnson &...

Read More...

Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors – GlobeNewswire

Wednesday, June 3rd, 2020

DOYLESTOWN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Companys Board of Advisors.

Mr. Tormeys most recent position was CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease. For over four decades, Mr. Tormey has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known life sciences companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson).

"Its really great to have Terry join our corporate advisory board and team of experts at Kannalife. His experience, vision and extraordinary body of knowledge in the life sciences industry come at a perfect time for us as we start to design our commercialization and distribution plan for Atopidine, said Dean Petkanas, CEO of Kannalife.

I am honored to serve as an advisor to Kannalife. They have remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN), which, when approved, will help improve the lives of hundreds of thousands of patients, Tormey said.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

Atopidine is Kannalifes novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.

KLS-13019 is Kannalifes leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View post:
Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors - GlobeNewswire

Read More...

Neuropathy Pain Treatment Market 2020| Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments And…

Wednesday, June 3rd, 2020

The market research report published by QYResearch is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Neuropathy Pain Treatment market. It informs readers about key trends and opportunities in the global Neuropathy Pain Treatment market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Neuropathy Pain Treatment market.

Key companies operating in the global Neuropathy Pain Treatment market include , Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals, Neuropathy Pain Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1436343/global-neuropathy-pain-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Neuropathy Pain Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Neuropathy Pain Treatment Market Segment By Type:

, Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Other

Global Neuropathy Pain Treatment Market Segment By Application:

, Retail Pharmacies, Hospitals, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Neuropathy Pain Treatment market.

Key companies operating in the global Neuropathy Pain Treatment market include , Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals, Neuropathy Pain Treatment

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1436343/global-neuropathy-pain-treatment-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Neuropathy Pain Treatment Revenue1.4 Market Analysis by Type 1.4.1 Global Neuropathy Pain Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Calcium Channel Alpha 2-delta Ligands 1.4.3 Serotonin-norepinephrine Reuptake Inhibitors 1.4.4 Others1.5 Market by Application 1.5.1 Global Neuropathy Pain Treatment Market Share by Application: 2020 VS 2026 1.5.2 Retail Pharmacies 1.5.3 Hospitals 1.5.4 Others1.6 Coronavirus Disease 2019 (Covid-19): Neuropathy Pain Treatment Industry Impact 1.6.1 How the Covid-19 is Affecting the Neuropathy Pain Treatment Industry 1.6.1.1 Neuropathy Pain Treatment Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Neuropathy Pain Treatment Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Neuropathy Pain Treatment Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Neuropathy Pain Treatment Market Perspective (2015-2026)2.2 Neuropathy Pain Treatment Growth Trends by Regions 2.2.1 Neuropathy Pain Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Neuropathy Pain Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Neuropathy Pain Treatment Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Neuropathy Pain Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Neuropathy Pain Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Neuropathy Pain Treatment Players by Market Size 3.1.1 Global Top Neuropathy Pain Treatment Players by Revenue (2015-2020) 3.1.2 Global Neuropathy Pain Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Neuropathy Pain Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Neuropathy Pain Treatment Market Concentration Ratio 3.2.1 Global Neuropathy Pain Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Neuropathy Pain Treatment Revenue in 20193.3 Neuropathy Pain Treatment Key Players Head office and Area Served3.4 Key Players Neuropathy Pain Treatment Product Solution and Service3.5 Date of Enter into Neuropathy Pain Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Neuropathy Pain Treatment Historic Market Size by Type (2015-2020)4.2 Global Neuropathy Pain Treatment Forecasted Market Size by Type (2021-2026) 5 Neuropathy Pain Treatment Breakdown Data by Application (2015-2026)5.1 Global Neuropathy Pain Treatment Market Size by Application (2015-2020)5.2 Global Neuropathy Pain Treatment Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Neuropathy Pain Treatment Market Size (2015-2020)6.2 Neuropathy Pain Treatment Key Players in North America (2019-2020)6.3 North America Neuropathy Pain Treatment Market Size by Type (2015-2020)6.4 North America Neuropathy Pain Treatment Market Size by Application (2015-2020) 7 Europe7.1 Europe Neuropathy Pain Treatment Market Size (2015-2020)7.2 Neuropathy Pain Treatment Key Players in Europe (2019-2020)7.3 Europe Neuropathy Pain Treatment Market Size by Type (2015-2020)7.4 Europe Neuropathy Pain Treatment Market Size by Application (2015-2020) 8 China8.1 China Neuropathy Pain Treatment Market Size (2015-2020)8.2 Neuropathy Pain Treatment Key Players in China (2019-2020)8.3 China Neuropathy Pain Treatment Market Size by Type (2015-2020)8.4 China Neuropathy Pain Treatment Market Size by Application (2015-2020) 9 Japan9.1 Japan Neuropathy Pain Treatment Market Size (2015-2020)9.2 Neuropathy Pain Treatment Key Players in Japan (2019-2020)9.3 Japan Neuropathy Pain Treatment Market Size by Type (2015-2020)9.4 Japan Neuropathy Pain Treatment Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Neuropathy Pain Treatment Market Size (2015-2020)10.2 Neuropathy Pain Treatment Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Neuropathy Pain Treatment Market Size by Type (2015-2020)10.4 Southeast Asia Neuropathy Pain Treatment Market Size by Application (2015-2020) 11 India11.1 India Neuropathy Pain Treatment Market Size (2015-2020)11.2 Neuropathy Pain Treatment Key Players in India (2019-2020)11.3 India Neuropathy Pain Treatment Market Size by Type (2015-2020)11.4 India Neuropathy Pain Treatment Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Neuropathy Pain Treatment Market Size (2015-2020)12.2 Neuropathy Pain Treatment Key Players in Central & South America (2019-2020)12.3 Central & South America Neuropathy Pain Treatment Market Size by Type (2015-2020)12.4 Central & South America Neuropathy Pain Treatment Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Pfizer 13.1.1 Pfizer Company Details 13.1.2 Pfizer Business Overview and Its Total Revenue 13.1.3 Pfizer Neuropathy Pain Treatment Introduction 13.1.4 Pfizer Revenue in Neuropathy Pain Treatment Business (2015-2020)) 13.1.5 Pfizer Recent Development13.2 Depomed 13.2.1 Depomed Company Details 13.2.2 Depomed Business Overview and Its Total Revenue 13.2.3 Depomed Neuropathy Pain Treatment Introduction 13.2.4 Depomed Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.2.5 Depomed Recent Development13.3 Eli Lilly 13.3.1 Eli Lilly Company Details 13.3.2 Eli Lilly Business Overview and Its Total Revenue 13.3.3 Eli Lilly Neuropathy Pain Treatment Introduction 13.3.4 Eli Lilly Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.3.5 Eli Lilly Recent Development13.4 Endo 13.4.1 Endo Company Details 13.4.2 Endo Business Overview and Its Total Revenue 13.4.3 Endo Neuropathy Pain Treatment Introduction 13.4.4 Endo Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.4.5 Endo Recent Development13.5 Grnenthal Group 13.5.1 Grnenthal Group Company Details 13.5.2 Grnenthal Group Business Overview and Its Total Revenue 13.5.3 Grnenthal Group Neuropathy Pain Treatment Introduction 13.5.4 Grnenthal Group Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.5.5 Grnenthal Group Recent Development13.6 Arbor Pharmaceuticals 13.6.1 Arbor Pharmaceuticals Company Details 13.6.2 Arbor Pharmaceuticals Business Overview and Its Total Revenue 13.6.3 Arbor Pharmaceuticals Neuropathy Pain Treatment Introduction 13.6.4 Arbor Pharmaceuticals Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.6.5 Arbor Pharmaceuticals Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Neuropathy Pain Treatment Market 2020| Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments And...

Read More...

Neuropathy Pain Treatment Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – WaterCloud News

Wednesday, June 3rd, 2020

Others

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Neuropathy Pain Treatment market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=275286&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Neuropathy Pain Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Market Research Intellect

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Neuropathy Pain Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Neuropathy Pain Treatment Market, By Deployment Model

5.1 Overview

6 Neuropathy Pain Treatment Market, By Solution

6.1 Overview

7 Neuropathy Pain Treatment Market, By Vertical

7.1 Overview

8 Neuropathy Pain Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Neuropathy Pain Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=275286&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Neuropathy Pain Treatment Market Size, Neuropathy Pain Treatment Market Trends, Neuropathy Pain Treatment Market Growth, Neuropathy Pain Treatment Market Forecast, Neuropathy Pain Treatment Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Follow this link:
Neuropathy Pain Treatment Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Read More...

Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN (eribulin mesylate) plus KEYTRUDA (pembrolizumab) in Patients…

Wednesday, June 3rd, 2020

This open-label, single-arm, multicenter, Phase 1b/2 study enrolled patients with mTNBC who had previously received zero to two systemic therapies for metastatic disease and were stratified by prior number of therapy (Stratum 1 = 0 prior therapies; Stratum 2 = 1-2 prior therapies). As there were no dose-limiting toxicities observed in Phase 1, patients received the recommended Phase 2 dose of eribulin (1.4 mg/m2 intravenously on Day 1 and Day 8) and pembrolizumab (200 mg intravenously on Day 1) of a 21-day cycle. At the time of data cutoff (July 31, 2019), 167 patients were enrolled (of which 149 patients had confirmed PD-L1 status). The primary objectives were safety and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent imaging review. Secondary objectives included progression free survival (PFS), overall survival (OS), duration of response (DOR) and clinical benefit rate (CBR) overall and by PD-L1 status. Previous findings from ENHANCE 1 were presented during a Spotlight Session at the San Antonio Breast Cancer Symposium (SABCS) in 2017.

Updated findings presented during ASCO20 showed:

The most common treatment-emergent adverse events were fatigue (66%), nausea (57%), peripheral sensory neuropathy (41%), alopecia (40%), and constipation (37%). No deaths were considered treatment related. The most common possibly immune-related TEAEs for pembrolizumab (occurring in >3% of patients) were hypothyroidism (18%), pneumonitis (11%), hyperthyroidism (8%) and infusion-related reaction (3%).

"Treatment options for metastatic triple-negative breast cancer remain limited, despite advances in the field," said Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group at Eisai. "As a human health care company, we are committed to addressing cancers that remain difficult to treat, and this is evident in our ongoing investigation in triple-negative disease. As long as unmet needs exist, Eisai will persist in our efforts to innovate for patients."

This release discusses an investigational use for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Previously, data from ENHANCE 1 was reported at the San Antonio Breast Cancer Symposium in 2016 and 2017.

The study is being conducted under an existing clinical trial collaboration agreement between Eisai and Merck.

About HALAVEN(eribulin mesylate) InjectionHALAVEN (eribulin mesylate) injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine spongeHalichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.

Important Safety Information

Warnings and Precautions

Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Patients with mBC with elevated liver enzymes >3 ULN and bilirubin >1.5 ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.

Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.

Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

Adverse ReactionsIn patients with mBC receiving HALAVEN, the most common adverse reactions (25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).

Use in Specific PopulationsLactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.

Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.

For more information about HALAVEN, clickherefor the full Prescribing Information.

HALAVEN is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

About Eisai Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.

For more information about Eisai, please visit http://www.eisai.com (for global), us.eisai.com(for U.S.) or http://www.eisai.eu (for Europe, Middle East, Africa), and connect with us on Twitter (U.S.and global) and LinkedIn(for U.S.).

SOURCE Eisai Inc.

http://www.eisai.com

Go here to see the original:
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN (eribulin mesylate) plus KEYTRUDA (pembrolizumab) in Patients...

Read More...

Medical Foods Market Predicted to Accelerate the Growth by 2017-2025 – Medic Insider

Wednesday, June 3rd, 2020

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Originally posted here:
Medical Foods Market Predicted to Accelerate the Growth by 2017-2025 - Medic Insider

Read More...

Page 13«..10..12131415..20..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick